» Articles » PMID: 35279762

Health Care Professionals Overestimate the Risk for Locoregional Recurrences After Breast Cancer Treatment Depending on Their Specialty

Overview
Specialty Oncology
Date 2022 Mar 13
PMID 35279762
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: For the implementation of personalised surveillance, it is important to create more awareness among HCPs with regard to the risk for locoregional recurrences (LRRs). The aim of this study is to evaluate the current awareness and estimations of individual risks for LRRs after completion of primary treatment for breast cancer among health care professionals (HCPs) in the Netherlands, without using any prediction tools.

Methods: A cross-sectional survey was performed among 60 HCPs working in breast cancer care in seven Dutch hospitals and 25 general practitioners (GPs). The survey consisted of eleven realistic surgically treated breast cancer cases. HCPs were asked to estimate the 5-year risk for LRRs for each case, which was compared to the estimations by the INFLUENCE-nomogram using one-sample Wilcoxon tests. Differences in estimations between HCPs with different specialities were determined using Kruskal-Wallis tests and Dunn tests.

Results: HCPs tended to structurally overestimate the 5-year risk for LRR on each case. Average overestimations ranged from 4.8 to 26.1%. Groups of HCPs with varying specialities differed significantly in risk estimations. GPs tended to overestimate the risk for LRRs on average the most (15.0%) and medical oncologists had the lowest average overestimation (2.7%).

Conclusions: It is important to create more awareness of the risk for LRRs, which is a pre-requisite for the implementation of personalised surveillance after breast cancer. Besides education for HCPs, the use of prediction models such as the INFLUENCE-nomogram can support in estimating an objective estimate of each individual patient's risk.

Citing Articles

Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands.

Rajan K, Nijveldt J, Verheijen S, Siesling S, Beek M, Francken A Breast Cancer Res Treat. 2024; 207(3):633-640.

PMID: 38874687 DOI: 10.1007/s10549-024-07391-x.


The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review.

van Maaren M, van Hoeve J, Korevaar J, van Hezewijk M, Siemerink E, Zeillemaker A Support Care Cancer. 2024; 32(5):323.

PMID: 38695938 PMC: 11065941. DOI: 10.1007/s00520-024-08530-2.


The underused potential of breast conserving therapy after neoadjuvant system treatment - Causes and solutions.

Pfob A, Dubsky P Breast. 2023; 67:110-115.

PMID: 36669994 PMC: 9982288. DOI: 10.1016/j.breast.2023.01.008.

References
1.
Ankersmid J, Drossaert C, van Riet Y, Strobbe L, Siesling S . Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance. J Cancer Surviv. 2022; 17(5):1471-1479. PMC: 10442247. DOI: 10.1007/s11764-022-01178-z. View

2.
Ankersmid J, van Hoeve J, Strobbe L, van Riet Y, van Uden-Kraan C, Siesling S . Follow-up after breast cancer: Variations, best practices, and opportunities for improvement according to health care professionals. Eur J Cancer Care (Engl). 2021; 30(6):e13505. PMC: 9285965. DOI: 10.1111/ecc.13505. View

3.
Zikmund-Fisher B, Janz N, Hawley S, Griffith K, Sabolch A, Jagsi R . Communication of Recurrence Risk Estimates to Patients Diagnosed With Breast Cancer. JAMA Oncol. 2016; 2(5):684-686. DOI: 10.1001/jamaoncol.2015.6416. View

4.
van der Sangen M, Scheepers S, Poortmans P, Luiten E, Nieuwenhuijzen G, Voogd A . Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: optimization of long-term follow-up strategies. Breast. 2012; 22(3):351-6. DOI: 10.1016/j.breast.2012.08.006. View

5.
Witteveen A, Vliegen I, Sonke G, Klaase J, IJzerman M, Siesling S . Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat. 2015; 152(3):627-36. PMC: 4519578. DOI: 10.1007/s10549-015-3490-4. View